Bluejay Diagnostics (BJDX) AI Stock Analysis

• Market Cap: $1.64M
• Dividend Yield: N/A
• Average Volume (3M): 5.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 97.70%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 453,533
• 10 Day Avg. Volume: 15,571,172
• 30 Day Avg. Volume: 5,266,425
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: -0.79
• Enterprise Value/Revenue: -6.00
• Enterprise Value/Gross Profit: 93.82
• Enterprise Value/Ebitda: 0.19
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $0.86 ▲(31.85% Upside)

The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, and sustained negative free cash flow) despite low debt. Technicals add only modest support with a short-term bounce but a longer-term downtrend. Corporate events are positive for operational progress, but long regulatory/financing timelines and a negative P/E keep overall risk elevated.

Positive Factors

In-house IL-6 Supply

Commercial-scale IL-6 antibody production gives Bluejay a large, internal supply to support cartridge manufacturing. This reduces reliance on third-party suppliers, lowers per-unit risk and cost, and materially improves operational readiness to scale consumable production once validated.

Low Leverage

Very low debt relative to equity reduces near-term insolvency risk for a pre-commercial developer. Limited fixed obligations extend financial flexibility to progress clinical work and regulatory steps without immediate pressure from creditors, preserving optionality for execution.

Targeted Clinical Market

A focus on rapid, point-of-care immunoassays for acute care and sepsis targets a structural clinical need where faster diagnostics materially affect treatment. Success would create durable consumable revenue and potential differentiation in hospital acute-care workflows.

Negative Factors

No Revenue / Cash Burn

The company is effectively pre-commercial with zero trailing revenue and persistent negative operating and free cash flow. Ongoing cash burn creates a material financing dependency, increasing dilution risk and uncertainty about the timing of sustainable, self-funded operations.

Regulatory Timeline Risk

A multi-year target for 510(k) submission tied to additional funding means commercialization timing is uncertain. Extended regulatory timelines raise cumulative development costs, delay revenue generation, and increase the likelihood of milestone slips or additional clinical requirements.

Eroding Equity Base

Material shrinkage in equity reflects cumulative losses and cash consumption, eroding the balance sheet cushion. A smaller equity base heightens vulnerability to financing delays, signals likely future dilution, and reduces resilience against execution setbacks during commercialization.

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Bluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary

Financial profile remains high-risk: the company is effectively pre-commercial with $0 TTM revenue, large and persistent losses (TTM operating loss ~-$7.0M; net loss ~-$6.9M), and continued cash burn (TTM operating/FCF ~-$6.3M). A partial offset is low leverage (debt ~ $0.14M vs equity ~ $3.69M), but equity has shrunk materially over time, keeping dilution/financing risk elevated.

Income Statement

The company remains pre-commercial, with revenue at $0 in TTM (Trailing-Twelve-Months) and most annual periods (except 2022 at ~$0.25M). Losses are large and persistent, with TTM operating loss of about $7.0M and net loss of about $6.9M, showing limited evidence of meaningful operating leverage so far. A modest positive is that the TTM net loss is smaller than 2024, but profitability is still far from breakeven and margins are deeply negative.

Balance Sheet

Leverage is low, with TTM debt of ~$0.14M against equity of ~$3.69M (low debt relative to equity), which reduces near-term solvency risk. However, the equity base has declined significantly versus prior years (from ~$11.5M in 2022 to ~$3.7M TTM), reflecting ongoing losses and cash burn. Returns on equity are materially negative, indicating continued value dilution unless the company can scale revenue.

Cash Flow

Cash generation is weak, with TTM operating cash flow around -$6.3M and free cash flow around -$6.3M, indicating continued funding needs. Free cash flow burn improved versus 2024 (less negative), but TTM free cash flow growth is sharply negative, highlighting volatility and an uneven trajectory. Cash burn broadly tracks reported losses, suggesting limited non-cash addbacks and no clear path yet to self-funding operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	216.09K	0.00	0.00	249.04K	0.00	0.00
Gross Profit	-13.83K	-199.10K	-780.96K	48.91K	-145.72K	-157.04K
EBITDA	-6.74M	-6.70M	-9.17M	-9.01M	-3.08M	-1.04M
Net Income	-6.85M	-7.72M	-9.95M	-9.30M	-3.73M	-1.13M
Balance Sheet
Total Assets	4.89M	6.66M	4.87M	13.52M	21.02M	1.52M
Cash, Cash Equivalents and Short-Term Investments	3.08M	4.30M	2.21M	10.11M	19.05M	912.36K
Total Debt	142.99K	222.25K	352.98K	492.62K	0.00	1.06M
Total Liabilities	1.20M	927.92K	1.97M	1.98M	637.16K	5.72M
Stockholders Equity	3.69M	5.73M	2.89M	11.54M	20.38M	-4.21M
Cash Flow
Free Cash Flow	-6.34M	-8.13M	-9.02M	-8.94M	-4.39M	-508.71K
Operating Cash Flow	-6.34M	-7.82M	-8.31M	-7.74M	-4.37M	-508.71K
Investing Cash Flow	-1.13K	-306.78K	-704.17K	-1.20M	-23.95K	0.00
Financing Cash Flow	3.67M	10.22M	1.11M	8.07K	22.53M	1.33M

Bluejay Diagnostics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Neutral. The current price of 0.65 is below the 20-day moving average (MA) of 2.90, below the 50-day MA of 3.72, and below the 200-day MA of 6.17, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 58.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BJDX.

Bluejay Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BJDX	46 Neutral	$1.64M	-0.03	-126.20%	―	―	97.70%
AEMD	45 Neutral	$2.43M	-0.05	-191.39%	―	―	76.53%
TIVC	45 Neutral	$3.01M	-0.13	-178.18%	―	-49.63%	82.22%
VERO	40 Underperform	$2.36M	-0.03	-854.61%	―	-12.39%	44.61%
DHAI	37 Underperform	$2.09K	>-0.01	―	―	―	―

Bluejay Diagnostics Corporate Events

Bluejay Diagnostics Scales IL-6 Antibody Production Capacity

On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a key biomarker for inflammatory and critical-care applications, with both antibody types meeting internal performance criteria for use in Symphony cartridge manufacturing. Internal testing showed acceptable binding, specificity and signal performance for the monoclonal detection antibodies, and the company now estimates its IL-6 antibody inventory could support production of more than nine million Symphony cartridges while also having the capability to produce additional antibodies, marking a significant operational milestone for scaling the Symphony platform even as the system remains under development and subject to further validation and regulatory review.

Bluejay Diagnostics Reports Q3 Results and Updates

On November 10, 2025, Bluejay Diagnostics announced its third-quarter financial results and corporate updates, highlighting advancements in clinical milestones and strategic partnerships. The company reported progress in the SYMON-II clinical trial, aiming for FDA clearance and product commercialization, and completed a private placement transaction in October 2025. Bluejay is focused on sepsis diagnostics, with plans to submit a 510(k) application to the FDA in 2027, contingent on securing further financing.